Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

SMAD4 and the TGFβ Pathway in Patients with Pancreatic Ductal Adenocarcinoma

16 May 2020

Abstract excerpt

Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer death worldwide. PDAC is an aggressive disease with an 11-month median overall survival and a five-year survival of less than 5%. Incidence of PDAC is constantly increasing and is predicted to become the second leading cause of cancer in Western countries within a decade. Despite research and therapeutic development, current knowledge...

Topics

Join the communities discussing this publication.

Metabolism, Diabetes, and Cancer
Pancreatic and Hepatic Oncology Research
TGF-β signaling in diseases

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 32429474
DOI: 10.3390/ijms21103534

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

SMAD4 and the TGFβ Pathway in Patients with Pancreatic Ductal AdenocarcinomaPMID 32429474Read ↗

The TGF-β/Smad4 Signaling Pathway in Pancreatic Carcinogenesis and Its Clinical SignificanceSemantic proximity Read ↗

New insight into the role of SMAD4 mutation/deficiency in the prognosis and therapeutic resistance of pancreatic ductal adenocarcinomas.Semantic proximity Read ↗

The role of TGF-β/SMAD4 signaling in cancer.Semantic proximity Read ↗

Alteration of Transforming Growth Factor β Signaling Pathway Predicts Worse Prognosis in Pancreatic Ductal Adenocarcinoma.Semantic proximity Read ↗

SMAD4 Deficiency Promotes Pancreatic Cancer Progression and Confers Susceptibility to TGFβ Inhibition.Semantic proximity Read ↗

Two sides of the story? Smad4 loss in pancreatic cancer versus head‐and‐neck cancerSemantic proximity Read ↗

SMAD4 loss triggers the phenotypic changes of pancreatic ductal adenocarcinoma cells.Semantic proximity Read ↗

Molecular Pathogenesis of Pancreatic Cancer.Semantic proximity Read ↗

Circadian Dysregulation of the TGFβ/SMAD4 Pathway Modulates Metastatic Properties and Cell Fate Decisions in Pancreatic Cancer CellsSemantic proximity Read ↗

Prognostic role and clinicopathological features of SMAD4 gene mutation in pancreatic cancer: a systematic review and meta-analysis.Semantic proximity Read ↗

Smad4-mediated TGF-β signaling in tumorigenesisSemantic proximity Read ↗

SMAD4 and its role in pancreatic cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.